Trials / Sponsors / John Kirkwood
John Kirkwood
Academic / Other · 7 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in U Locally Advanced Melanoma | — | 2025-11-19 |
| Recruiting | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi Melanoma | — | 2025-02-20 |
| Terminated | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Unresectable Melanoma | Phase 1 / Phase 2 | 2021-10-06 |
| Completed | Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Melanoma | Phase 2 | 2019-03-29 |
| Completed | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma Melanoma | Phase 1 | 2013-10-01 |
| Completed | Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions Atypical Nevi, Melanoma | EARLY_Phase 1 | 2012-08-01 |
| Terminated | Dendritic Cells (DC) Vaccine for Metastatic Melanoma Metastatic Melanoma | Phase 2 | 2002-10-01 |